# A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

> **NCT03565068** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 75 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** MK-8189
- **DRUG:** Placebo
- **DRUG:** Background AAP Therapy

## Key facts

- **NCT ID:** NCT03565068
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-20
- **Primary completion:** 2020-04-03
- **Final completion:** 2020-04-03
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2021-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03565068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03565068, "A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03565068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*